Monte Rosa Therapeutics Says First Patient Dosed In Modefire-1, Phase 2 Study Evaluating MRT-2359 In Combination With Apalutamide In Patients With mCRPC With AR Mutations
Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safetyUpdated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with
Monte Rosa started testing a new cancer medicine (MRT-2359) combined with another drug in patients with a specific type of prostate cancer. Doctors will watch how well it works and if it's safe, which helps the company learn if this treatment could help people.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.